Fulcrum Therapeutics Stock Analysis
| FULC Stock | USD 3.21 0.06 1.90% |
Fulcrum Therapeutics is undervalued with Real Value of 3.68 and Hype Value of 3.21. The main objective of Fulcrum Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Fulcrum Therapeutics is worth, separate from its market price. There are two main types of Fulcrum Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Fulcrum Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Fulcrum Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Fulcrum |
Fulcrum Stock Analysis Notes
About 97.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulcrum Therapeutics recorded a loss per share of 0.16. The entity had not issued any dividends in recent years. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people. To learn more about Fulcrum Therapeutics call Bryan Stuart at 617 651 8851 or check out https://www.fulcrumtx.com.Fulcrum Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fulcrum Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fulcrum Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with profit before overhead, payroll, taxes, and interest of 16.61 M. | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fulcrum Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors |
Fulcrum Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fulcrum Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Fulcrum Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 170.03 M.Fulcrum Profitablity
The company has Profit Margin (PM) of (0.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25.Technical Drivers
As of the 24th of March, Fulcrum Therapeutics shows the Variance of 12.64, mean deviation of 2.66, and Standard Deviation of 3.56. Fulcrum Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fulcrum Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Fulcrum Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Fulcrum Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Fulcrum Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulcrum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulcrum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulcrum Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fulcrum Therapeutics Outstanding Bonds
Fulcrum Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fulcrum Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fulcrum bonds can be classified according to their maturity, which is the date when Fulcrum Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US359678AC31 Corp BondUS359678AC31 | View | |
| HB Fuller 4 Corp BondUS359694AB24 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Fulcrum Therapeutics Predictive Daily Indicators
Fulcrum Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fulcrum Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 4588.37 | |||
| Daily Balance Of Power | 0.75 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 3.22 | |||
| Day Typical Price | 3.22 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.06 |
Fulcrum Therapeutics Forecast Models
Fulcrum Therapeutics' time-series forecasting models are one of many Fulcrum Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fulcrum Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Fulcrum Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fulcrum Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fulcrum shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fulcrum Therapeutics. By using and applying Fulcrum Stock analysis, traders can create a robust methodology for identifying Fulcrum entry and exit points for their positions.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fulcrum Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |